Abstract:Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by myeloproliferation, bone marrow fibrosis, splenomegaly, and constitutional symptoms related to pro-inflammatory cytokine signaling. Biologically, MF is characterized by constitutive activation of JAK-STAT signaling; accordingly, JAK inhibitors have been rationally developed to treat MF. Following the initial approval of ruxolitinib in 2011, three additional agents have been approved: fedratinib, pacritinib, and momelotinib. As these therapies are non-curative, allogeneic stem cell transplantation remains a key treatment modality and patients with MF who are deemed candidates should be referred to a transplant center. This potentially curative but toxic approach is typically reserved for patients with higher-risk disease, and JAK inhibitors are recommended in the pre-transplant setting. JAK inhibitors have proven effective at managing splenomegaly and constitutional symptoms and should be started early in the disease course in patients presenting with these clinical manifestations; asymptomatic patients may initially be followed with close surveillance. Drug-related myelosuppression has been a challenge with initial JAK inhibitors, particularly in patients presenting with a cytopenic phenotype. However, newer agents, namely pacritinib and momelotinib, have proven more effective in this setting and are approved for patients with significant thrombocytopenia and anemia, respectively. Resistance or disease progression is clinically challenging and may be defined by several possible events, such as increasing splenomegaly or progression to accelerated or blast phase disease. However, with multiple JAK inhibitors now approved, sequencing of these agents appears poised to improve outcomes. Additionally, novel JAK inhibitors and JAK inhibitor-based combinations are in clinical development.

A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases

Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor‐naïve Patients with Myelofibrosis: Results of a Phase II Trial

Janus kinase 2 inhibitors in myeloproliferative disorders

Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions

Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

Experimental therapeutics for patients with myeloproliferative neoplasias

Research progress of JAK1/2 inhibitors in the treatment of myeloproliferative neoplasms

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis

Emerging drug profile: JAK inhibitors

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

Advances in understanding and management of myeloproliferative neoplasms

Managing side effects of JAK inhibitors for myelofibrosis in clinical practice

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.

Jak-2 positive myeloproliferative neoplasms

How I individualize selection of JAK inhibitors for patients with myelofibrosis

Developmental Therapeutics in Myeloproliferative Neoplasms